Page last updated: 2024-09-03

imatinib mesylate and Kaposi Sarcoma

imatinib mesylate has been researched along with Kaposi Sarcoma in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (81.82)	29.6817
2010's	2 (18.18)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Colegio, OR; Liu, LS	1
Aboulafia, D; Dezube, BJ; Honda, K; Koon, HB; Krown, SE; Lee, JY; Noy, A; Rapisuwon, S; Reid, EG; Rudek, MA; Wang, Z	1
Kapoor, S	1
Campione, E; Chimenti, S; Di Marcantonio, D; Diluvio, L; Francesconi, A; Orlandi, A; Paternò, EJ; Terrinoni, A	1
Bell, YC; Druker, BJ; Früh, K; Griffith, DJ; Heinrich, MC; Jarvis, MA; Luukkonen, BG; Moses, AV; Nelson, JA; Raggo, C; Ruhl, R; Wait, CL	2
Bubley, GJ; Chatis, P; Crosby, K; Dezube, BJ; Egorin, MJ; Koon, HB; Masiello, D; Miller, TE; Pantanowitz, L; Proper, J; Smith, B; Tahan, SR; Weeden, W	1
Senior, K	1
Früh, K; McAllister, SC; Moses, AV	1
Correa-Rotter, R; Volkow, P; Zinser, JW	1
Ascione, B; Basciani, S; Cauda, R; Gnessi, L; Lucia, MB; Malorni, W; Mariani, S; Matarrese, P; Straface, E; Vona, R	1

Reviews

2 review(s) available for imatinib mesylate and Kaposi Sarcoma

Article	Year
Molecularly targeted therapies for nonmelanoma skin cancers. International journal of dermatology, 2013, Volume: 52, Issue:6 Topics: Anilides; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cetuximab; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Piperazines; Pyridines; Pyrimidines; Sarcoma, Kaposi; Sirolimus; Skin Neoplasms	2013
Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma. Pharmacogenomics, 2005, Volume: 6, Issue:3 Topics: Antineoplastic Agents; Benzamides; Genomics; Heme Oxygenase-1; Herpesvirus 8, Human; Humans; Imatinib Mesylate; Mesoporphyrins; Models, Biological; Oligonucleotides, Antisense; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma, Kaposi	2005

Article

Year

Molecularly targeted therapies for nonmelanoma skin cancers.

International journal of dermatology, 2013, Volume: 52, Issue:6

Topics: Anilides; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cetuximab; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Piperazines; Pyridines; Pyrimidines; Sarcoma, Kaposi; Sirolimus; Skin Neoplasms

2013

Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma.

Pharmacogenomics, 2005, Volume: 6, Issue:3

Topics: Antineoplastic Agents; Benzamides; Genomics; Heme Oxygenase-1; Herpesvirus 8, Human; Humans; Imatinib Mesylate; Mesoporphyrins; Models, Biological; Oligonucleotides, Antisense; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma, Kaposi

2005

Trials

2 trial(s) available for imatinib mesylate and Kaposi Sarcoma

Article	Year
Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-10, Volume: 32, Issue:5 Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antineoplastic Agents; Benzamides; Cytokines; Disease Progression; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Kaposi; Time Factors; Treatment Outcome; United States	2014
Imatinib-induced regression of AIDS-related Kaposi's sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-10, Volume: 23, Issue:5 Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antineoplastic Agents; Benzamides; Biopsy; Diarrhea; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Sarcoma, Kaposi; Signal Transduction; Skin Neoplasms; Vascular Endothelial Growth Factor A	2005

Article

Year

Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-10, Volume: 32, Issue:5

Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antineoplastic Agents; Benzamides; Cytokines; Disease Progression; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Kaposi; Time Factors; Treatment Outcome; United States

2014

Imatinib-induced regression of AIDS-related Kaposi's sarcoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-10, Volume: 23, Issue:5

Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antineoplastic Agents; Benzamides; Biopsy; Diarrhea; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Sarcoma, Kaposi; Signal Transduction; Skin Neoplasms; Vascular Endothelial Growth Factor A

2005

Other Studies

7 other study(ies) available for imatinib mesylate and Kaposi Sarcoma

Article	Year
The therapeutic benefits of heme oxygenase (HO-1) inhibition in the management of systemic malignancies besides hepatocellular carcinomas. International journal of cancer, 2009, Aug-01, Volume: 125, Issue:3 Topics: Antineoplastic Agents; Benzamides; Carcinoma, Hepatocellular; Enzyme Inhibitors; Heme Oxygenase-1; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Nasopharyngeal Neoplasms; Neoplasms; Piperazines; Protoporphyrins; Pyrimidines; Sarcoma, Kaposi	2009
Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia. Clinical therapeutics, 2009, Volume: 31, Issue:11 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Benzamides; DNA, Viral; Fusion Proteins, bcr-abl; Herpesvirus 8, Human; HIV Seronegativity; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Kaposi; Skin	2009
Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. Journal of virology, 2002, Volume: 76, Issue:16 Topics: Base Sequence; Benzamides; Cell Adhesion; Cell Division; Cell Line; Cell Size; Cell Transformation, Neoplastic; Cell Transformation, Viral; DNA; Endothelium, Vascular; Gene Expression Profiling; Herpesvirus 8, Human; Humans; Imatinib Mesylate; Neovascularization, Pathologic; Piperazines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Proto-Oncogenes; Pyrimidines; Sarcoma, Kaposi; Signal Transduction; Stem Cell Factor; Up-Regulation	2002
A functional genomics approach to Kaposi's sarcoma. Annals of the New York Academy of Sciences, 2002, Volume: 975 Topics: Benzamides; Cell Line, Transformed; Cell Transformation, Neoplastic; Cell Transformation, Viral; Endothelium, Vascular; Enzyme Inhibitors; Gene Expression Profiling; Genomics; Herpesvirus 8, Human; Humans; Imatinib Mesylate; Oligonucleotide Array Sequence Analysis; Piperazines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Antisense; Sarcoma, Kaposi; Virulence	2002
Growth-factor inhibition as therapy for Kaposi's sarcoma. The Lancet. Oncology, 2005, Volume: 6, Issue:1 Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Administration Schedule; Humans; Imatinib Mesylate; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Sarcoma, Kaposi	2005
Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not". BMC nephrology, 2007, Mar-27, Volume: 8 Topics: Aged, 80 and over; Benzamides; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Imatinib Mesylate; Immunohistochemistry; Kidney Failure, Chronic; Kidney Transplantation; Male; Neoplasm Staging; Piperazines; Pyrimidines; Retreatment; Risk Assessment; Sarcoma, Kaposi; Sirolimus; Skin Neoplasms; Treatment Outcome	2007
Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells. FEBS letters, 2007, Dec-22, Volume: 581, Issue:30 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Lysosomes; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sarcoma, Kaposi; Vacuoles	2007